Abstract
Angiogenesis is a tightly regulated process that leads to the formation of new blood vessels in limited physiological conditions, and can also occur under pathological situations as retinopathies, arthritis, endometriosis and cancer. Enhanced angiogenesis is present in tumors that need new blood capillaries to grow, remove metabolic waste and transport the cells to locations distal to the primary tumor, facilitating metastasis formation. For these reasons, blockade of angiogenesis is an attractive approach for the treatment of both solid and haematological malignancies. Antiangiogenic therapy should be less toxic in comparison with conventional treatments such as chemotherapy, being angiogenesis a process relatively restricted to the growing tumor. The Src family of tyrosine kinases has been implicated in the intracellular signaling cascade that acts downstream of cell surface receptors to elicit different cellular functions, including growth, proliferation, adhesion and motility. Src kinases are frequently activated in human malignancies, causing tumor progression, metastasis formation and deregulating expression of proangiogenic molecules. This review reports several studies performed by different authors demonstrating the involvement of Src tyrosine kinases in angiogenesis by regulating different signalling pathways. Moreover, we report selective Src inhibitors for which a direct involvement with angiogenesis has been demonstrated, even if every Src inhibitor could potentially possesses also antiangiogenic properties. Biological data, structures and mechanisms of action of selected molecules, in terms of Src protein-inhibitor interactions, are also reported.
Keywords: Angiogenesis, cancer, tyrosine kinase, Src, VEGF, FGF, small molecules inhibitors, binding mode
Current Pharmaceutical Design
Title: Src Inhibitors and Angiogenesis
Volume: 13 Issue: 21
Author(s): S. Schenone, F. Manetti and M. Botta
Affiliation:
Keywords: Angiogenesis, cancer, tyrosine kinase, Src, VEGF, FGF, small molecules inhibitors, binding mode
Abstract: Angiogenesis is a tightly regulated process that leads to the formation of new blood vessels in limited physiological conditions, and can also occur under pathological situations as retinopathies, arthritis, endometriosis and cancer. Enhanced angiogenesis is present in tumors that need new blood capillaries to grow, remove metabolic waste and transport the cells to locations distal to the primary tumor, facilitating metastasis formation. For these reasons, blockade of angiogenesis is an attractive approach for the treatment of both solid and haematological malignancies. Antiangiogenic therapy should be less toxic in comparison with conventional treatments such as chemotherapy, being angiogenesis a process relatively restricted to the growing tumor. The Src family of tyrosine kinases has been implicated in the intracellular signaling cascade that acts downstream of cell surface receptors to elicit different cellular functions, including growth, proliferation, adhesion and motility. Src kinases are frequently activated in human malignancies, causing tumor progression, metastasis formation and deregulating expression of proangiogenic molecules. This review reports several studies performed by different authors demonstrating the involvement of Src tyrosine kinases in angiogenesis by regulating different signalling pathways. Moreover, we report selective Src inhibitors for which a direct involvement with angiogenesis has been demonstrated, even if every Src inhibitor could potentially possesses also antiangiogenic properties. Biological data, structures and mechanisms of action of selected molecules, in terms of Src protein-inhibitor interactions, are also reported.
Export Options
About this article
Cite this article as:
S. Schenone , F. Manetti and M. Botta , Src Inhibitors and Angiogenesis, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039580
DOI https://dx.doi.org/10.2174/138161207781039580 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Current Genomics 15,16-dihydrotanshinone I Induces Apoptosis and Inhibits the Proliferation, Migration of Human Osteosarcoma Cell Line 143B in vitro
Anti-Cancer Agents in Medicinal Chemistry A Novel Method for Screening of Anti-Cancer Drugs: Availability of Screening in Acidic Medium
Recent Patents on Biomedical Engineering (Discontinued) Baculovirus Gene Delivery: A Flexible Assay Development Tool
Current Gene Therapy Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
Current Cancer Drug Targets Editorial
Recent Patents on Anti-Cancer Drug Discovery Delta Np63 alpha – Responsive microRNA Modulate the Expression of Metabolic Enzymes
Current Pharmaceutical Biotechnology Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry YB-1 Activities in Oncogenesis: Transcription and Translation
Current Cancer Therapy Reviews Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Development on PEG-modified Poly (Amino Acid) Copolymeric Micelles for Delivery of Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials Anaesthesia in Cancer Surgery: Can it Affect Cancer Survival?
Current Clinical Pharmacology Emulsomes Meet S-layer Proteins: An Emerging Targeted Drug Delivery System
Current Pharmaceutical Biotechnology Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Current Pharmaceutical Biotechnology